Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

Information

  • Research Project
  • 7575826
  • ApplicationId
    7575826
  • Core Project Number
    R43DK080529
  • Full Project Number
    5R43DK080529-02
  • Serial Number
    80529
  • FOA Number
    PA-07-280
  • Sub Project Id
  • Project Start Date
    3/1/2008 - 16 years ago
  • Project End Date
    2/28/2010 - 14 years ago
  • Program Officer Name
    DENSMORE, CHRISTINE L
  • Budget Start Date
    3/1/2009 - 15 years ago
  • Budget End Date
    2/28/2010 - 14 years ago
  • Fiscal Year
    2009
  • Support Year
    2
  • Suffix
  • Award Notice Date
    3/20/2009 - 15 years ago

Selective Cytopheresis Therapy in Systemic Inflammatory Response Syndrome

DESCRIPTION (provided by applicant): An extracorporeal device, named selective cytopheretic device (SCD), has been fabricated that sequesters activated leukocytes and inhibits their release of inflammatory proteins and cytokines. Leukocytes are major contributors to the pathogenesis and progression of many clinical inflammatory disorders, including the systemic inflammatory response syndrome (SIRS), sepsis and acute respiratory distress syndrome (ARDS). A large number of therapeutic approaches are under investigation to limit the activation and tissue accumulation of leukocytes at sites of inflammation in order to minimize tissue destruction and disease progression. This research proposal will evaluate this SCD on a well-developed porcine model of septic shock, SIRS and early ARDS. Various cardiovascular parameters, systemic cytokine levels, and pulmonary inflammation with bronchoalveolar lavage (BAL) parameters and time to death will be compared between treatment and sham treatment groups. The effects of membrane surface area and efficacy of a simplified circuit system on the ongoing multiorgan dysfunction and inflammatory processes will also be assessed. This proposal may suggest a manner of altering the systemic inflammatory response and may lead to a new therapeutic approach to sepsis, SIRS and ARDS.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    248465
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:248465\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INNOVATIVE BIOTHERAPIES, INC.
  • Organization Department
  • Organization DUNS
    143681240
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    48108
  • Organization District
    UNITED STATES